Navigation Links
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Date:8/20/2007

apan. Medicine (Baltimore). 2004;83:193-207.

(8) Gralnick HR, Vail M, McKeown LP et al. Activated platelets in

paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1995;91:697-702.

(9) Audebert HJ, Planck J, Eisenburg M, Schrezenmeier H, Haberl RL.

Cerebral ischemic infarction in paroxysmal nocturnal hemoglobinuria

report of 2 cases and updated review of 7 previously published

patients. J Neurol. 2005;252:1379-1386.

(10) Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin

prevents thrombosis in paroxysmal nocturnal haemoglobinuria (PNH).

Blood. 2003;102:3587-3591.

(11) Rosse WF, Nishimura J. Clinical manifestations of paroxysmal

nocturnal hemoglobinuria: present state and future problems. Int J

Hematol. 2003;77:113-120.

(12) Luzzatto L, Gianfaldoni G. Recent advances in biological and clinical

aspects of paroxysmal nocturnal hemoglobinuria. Int J Hematol.

2006;84:104-112.

(13) Hill A, Platts PJ, Smith A et al. The incidence and prevalence of

paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in

Yorkshire [abstract]. Blood. 2006;108(11):290a. Abstract 985.

(14) Johnson RJ, Hillmen P. Paroxysmal nocturnal hemoglobinemia: Nature's

gene therapy? J Clin Path: Mol Pathol. 2002;55:145-152.

(15) Wang, et al. Clinical significance of a minor population of

paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure

syndrome. Blood 2002;100:3897-3902.

(16) Iwanga, et al. Paroxysmal nocturnal haemoglobinuria clones in

patients with myelodysplastic syndromes. Brit J Haem. 1998;

102:465-474.

(17) Maciejewski, et al. Relationship between bone marrow failure

syndromes and the presence of glycophosphatidyl inositol-anchored

protein-deficient clones. Brit J Haem. 2001;115:1015
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Now available for sale, The ... support that prevents ankle sprains by cushioning the ankle ... fits securely around the outside of any shoe type ... comfort while still offering protection against sprains. With customers ...
(Date:1/23/2015)... MONMOUTH JUNCTION, N.J. , Jan. 23, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... surgery patients, announced the receipt of $385,642, net ... approved participant of the Technology Business Tax Certificate ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... Pharmaceuticals, Inc. (Nasdaq: AMPE ), a biopharmaceutical ... (Zertane™ completed two phase III studies, Ampion™-completed ... these drugs and engaged in further drug development, today ... the US Patent Office of an additional patent that ...
... March 19, 2012 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems ... an emerging leader in the development, assembly, marketing ... products, today announced its financial results for the ... (Logo: http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO ) ...
Cached Medicine Technology:Ampio Strengthens Patent Protection for Lead Drug Ampion™ 2Ampio Strengthens Patent Protection for Lead Drug Ampion™ 3Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 2Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 3Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 4Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 5Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 6Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 7Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 8Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 9Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 10Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 11Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 12Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 13Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 14Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 15
(Date:1/22/2015)... The U.S. Pharmacopeial Convention is pleased to ... Pharmacy Services at North Carolina State’s College of Veterinary ... Beal Award for Distinguished Volunteer Service—the organization’s highest award. ... contributions of volunteer experts to direct its work to ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Woodloch Pines, an ... has been selected by TripAdvisor as the number one best ... 6th best in the world for their annual Travelers’ Choice ... travel community . The website is home to millions of ...
(Date:1/22/2015)... Houston, TX (PRWEB) January 22, 2015 The ... Pro Bodybuilder Ben Pakulski to increase lean muscle by up ... This has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting ... shows that it is a step-by-step, scientific diet formula that ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The federal court ... the U.S. District Court, Southern District of West Virginia has ... in that proceeding’s first bellwether trial. In an Order dated ... new trial after finding that C.R. Bard had not proven ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining ... policy . , Auto insurance quotes help many drivers ... longer necessary to call an agent or visit an agency ... a single website: http://autocarinsurancebest.com/ . , Every business who ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2
... , , BOSTON, July 29 ... 2009, its annual summer scientific meeting, in Boston, July 29 - ... Anticipated attendance is more than 4,000. World-renowned leaders in the field ... diagnosis and medical, surgical and cosmetic treatment of skin, hair and ...
... , , MORRISTOWN, N.J., July ... leader in generic and specialty branded pharmaceuticals, today reported net income ... as detailed in the reconciliation table below, adjusted net income for ... an increase of $15.8 million or 29 percent. Adjusted EBITDA for ...
... , , , ... ) today announced that second quarter 2009 net income was $693.5 million, or ... income in the second quarter of 2008 was $750.5 million, or $1.44 per ... , "We are pleased with our earnings per share results for ...
... ... world , ... July 28, 2009 -- Announcing the first HelpDesk for GCP in the world. A much ... means to bring modern science and technology to diseased patients., , ,With the increase in ...
... Generation Rescue ... the autism community in order to help children and educate parents and medical professionals. , ... Los Angeles, CA (Vocus) July 29, 2009 -- ... meet the needs of the autism community in order to help children and educate parents and ...
... ... Provider Maximizes Performance with the TEDS Talent Management Suite. , ... Johnson City, TN (PRWEB) July 29, 2009 ... today the rollout of the TEDS® Talent Management Suite. TEDS is now live for ...
Cached Medicine News:Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 2Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 3Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 4Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 5Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 6Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 7Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 8Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 9Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 10Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 11Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 12Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 13Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 14Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 15Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 16Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 17Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 18Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 19Health News:WellPoint Reports Second Quarter 2009 Results 2Health News:WellPoint Reports Second Quarter 2009 Results 3Health News:WellPoint Reports Second Quarter 2009 Results 4Health News:WellPoint Reports Second Quarter 2009 Results 5Health News:WellPoint Reports Second Quarter 2009 Results 6Health News:WellPoint Reports Second Quarter 2009 Results 7Health News:WellPoint Reports Second Quarter 2009 Results 8Health News:WellPoint Reports Second Quarter 2009 Results 9Health News:WellPoint Reports Second Quarter 2009 Results 10Health News:WellPoint Reports Second Quarter 2009 Results 11Health News:WellPoint Reports Second Quarter 2009 Results 12Health News:WellPoint Reports Second Quarter 2009 Results 13Health News:WellPoint Reports Second Quarter 2009 Results 14Health News:WellPoint Reports Second Quarter 2009 Results 15Health News:WellPoint Reports Second Quarter 2009 Results 16Health News:WellPoint Reports Second Quarter 2009 Results 17Health News:WellPoint Reports Second Quarter 2009 Results 18
... Increased volume for use with 4, 8, ... bottom permits withdrawal of nearly all of the ... excess solution. Made of natural virgin polystyrene containing ... by irradiation. Dimensions: 78 mm W x 152 ...
Volume: 5 ml; Volume Graduation: 1/10 ml...
Precise, safe, and fatigue-free series pipetting using graduated pip...
An adhesive-backed hanger, designed for use where space is limited (fume hoods, sterile hoods, etc.). Sticks to any smooth, dry surface without damage. Resistant to chemicals and UV light....
Medicine Products: